Radiation plus drugs vs drugs alone for limited spread bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding targeted radiation to standard drug therapy can help people with a limited number of bladder or urinary tract cancer metastases. It's for those whose cancer has spread to a few spots that can be treated with full coverage radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of metastatic uroepithelial (bladder/urinary tract) cancer.
- Your cancer must be in no more than 3 different organs (or lymph node areas counted as one).
- You are between 18 and 80 years old and in generally good health (ECOG score 0-1).
- Your major organs (like liver, kidneys, blood) must be working well enough as shown by blood tests.
- You have not had brain metastases or more than 3 liver metastases, and you can tolerate standard drug therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
This trial tests whether adding targeted radiation therapy to standard drug treatment can help people with urothelial cancer that has spread to a few spots (up to 3 outside the brain). If you are starting your first or second round of systemic therapy, this study may be an option.
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
This study tests whether adding an immunotherapy drug (cemiplimab) with or without another drug (fianlimab) to radiation therapy can help treat bladder cancer that has not spread. The goal is to see if this combination could be an option for people who cannot have cisplatin chemotherapy.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.